Silexion Reports $2.5 Million Third-Quarter Net Loss as SIL204 Trial Begins
Silexion Therapeutics (SLXN) reported a Q3 2026 net loss of $2.5M, or $13.70 per share, with $4.8M in cash. The company began its Phase 2/3 SIL204 trial for pancreatic cancer. R&D expenses decreased to $1.3M from $2.2M YoY, while G&A expenses rose to $1.4M. Silexion raised $6.2M through offerings and share sales, and completed a 1-for-24 reverse split.
How this was made

The 30-second read
Why it matters
The earnings miss and cash position create immediate downside risk, while the trial initiation may attract future funding and partnership opportunities.
Market read
Micro‑cap biotech investors will weigh the loss against the trial start, likely leading to short‑term price pressure.
What to watch
Potential for upcoming data readouts and partnership interest not reflected in the loss figures.
Background
Silexion Therapeutics (NASDAQ: SLXN) disclosed its Q3 financials and announced the first patient dosing in its SIL204 trial for locally advanced pancreatic cancer.
Ticker impact
Silexion Therapeutics reported a Q3 net loss of $2.5M and launched the Phase 2/3 SIL204 trial for pancreatic cancer.
likely pressure as investors price in the loss and cash constraints
Quarterly loss and low cash typically weigh on micro‑cap biotech stocks; however, the start of a pivotal trial may temper the decline.
Market effects
Adds to the pipeline activity narrative in the oncology biotech sector.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche oncology investors.
Counterpoint
The trial start could be a catalyst for a short‑term rally if investors focus on future upside.
Key entities
- companySilexion Therapeutics
Clinical‑stage biotech focused on oncology.
- institutionTel Aviv Sourasky Medical Center
Site of the first patient dosing for the SIL204 trial.